Anti-hyperglycemic activity of moxonidine: Metabolic and molecular effects in obese spontaneously hypertensive rats

Blood Pressure

Volumn 7, Issue SUPPL. 3, 1998, Pages 32-39

  Friedman, Jacob E ^a   Ishizuka, Tatsuya ^a   Liu, Sha ^a   Farrell, Craig J ^a   Koletsky, Richard J ^a   Bedol, David ^a   Ernsberger, Paul ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

diabetes; free fatty acids; hypertension; imidazoline receptors; insulin receptors; insulin resistance; obesity; syndrome X; tyrosine phosphorylation

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; IMIDAZOLE DERIVATIVE; MOXONIDINE; IMIDAZOLINE RECEPTOR STIMULATING AGENT; INSULIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; DISEASE MODEL; FEMALE; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; MALE; METABOLISM; OBESITY; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; GLUCOSE METABOLISM; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; SYNDROME X;

ANIMALS; ANTIHYPERTENSIVE AGENTS; DISEASE MODELS, ANIMAL; FEMALE; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIC AGENTS; IMIDAZOLES; INSULIN RESISTANCE; MALE; OBESITY; RATS; RATS, INBRED SHR;

EID: 0032242079     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.1080/080370598438465     Document Type: Article

References (38)

1. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607. (Pubitemid 19004941)
2. Zavaroni I, Dall'Aglio E, Bonora E, Alpi O, Passeri M, Reaven GM. Evidence that multiple risk factors for coronary artery disease exist in persons with abnormal glucose tolerance. Am J Med 1987; 83: 609-12.
3. Daly P, Landsberg L. Hypertension in obesity and NIDDM: role of insulin and sympathetic nervous system. Diabetes Care 1991; 14: 240-8.
4. Brands MW, Hall JE, Van Vliet BN, et al. Obesity and hypertension: roles of hyperinslinemia, sympathetic nervous system and intrarenal mechanisms. J Nutr 1995; 125: 1725S-31.
5. Landsberg L. Diabetes, obesity and hypertension: role of insulin and the sympathetic nervous system. Cardiovasc Risk Factors 1993; 3: 153-8. (Pubitemid 23184273)
6. Periris AN, Mueller RA, Smith GA, Struve MF, Kissebah AH. Splanchnic insulin metabolism in obesity. J Clin Invest 1986; 78: 1648-57.
7. Krotkiewski M, Bjorntorp P, Sjostrom L, Smith U. Impact of obesity on metabolism in men and women. J Clin Invest 1983; 72: 1150-62.
8. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997; 45: 3-10. (Pubitemid 27009941)
9. Belivacqua S, Bonadonna R, Buzzigoli G, et al. Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects. Metab Clin Exp 1987; 36: 323-9.
10. Sako Y, Grill VE. A 48-hour lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and β-cell oxidation through a process likely coupled to fatty acid oxidation. Endocrinology 1990; 127: 1580-9. (Pubitemid 20315212)
11. Zou Y-P, Grill VE. Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. J Clin Invest 1994; 93: 870-6. (Pubitemid 24072831)
12. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997; 45: 3-10. (Pubitemid 27009941)
13. Belivacqua S, Bonadonna R, Buzzigoli G, et al. Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects. Metab Clin Exp 1987; 36: 323-9.
14. Kahn CR. Banting Lecture: Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 1994; 43: 1066-84. (Pubitemid 24230714)
15. DeFronzo RA. Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 1997; 5: 177-269.
16. White MF, Kahn CR. The insulin signaling system. J Biol Chem 1994; 269: 1-4. (Pubitemid 24026607)
17. Tamemoto H, Kadowaki T, Tobe K, et al. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 1994; 372: 182-6. (Pubitemid 24347838)
18. Goodyear LJ, Giorgino F, Sherman LA, et al. Insulin receptor phosphorylation, IRS-1 phosphorylation, and phosphatidylinositol 3-kinase are decreased in intact skeletal muscle strips from obese subjects. J Clin Invest 1995; 95: 2195-204.
19. Koletsky RJ, Ernsberger P. Obese SHR (Koletsky rat): a model for the interactions between obesity and hypertension. In: Sassard J, ed. Genetic hypertension. London: John Libbey, 1992: 373-5.
20. Takaya K, Ogawa Y, Hiaoka J, et al. Nonsense mutation of leptin receptor in the obese spontaneously hypertensive Koletsky rat. Nature Gen 1996; 14: 203-5.
21. Friedman JE, Ishizuka T, Liu S, et al. Reduced insulin receptor signaling in the obese spontaneously hypertensive Koletsky rat. Am J Phys 1997: in press.
22. Kaan EC, Bruckner R, Frohly P, et al. Effects of agmatine and moxonidine on glucose metabolism: an integrated approach towards pathophysiological mechanisms in cardiovascular metabolic disorders. Cardiovasc Risk Factors 1995; 5 (Suppl 1): 19-27.
23. Ernsberger P, Koletsky RJ, Collins LA, Bedol D. Sympathetic nervous system in salt-sensitive and obese hypertension: amelioration of multiple abnormalities by a central sympatholytic agent. Cardiovasc Drugs Ther 1996; 10: 275-82. (Pubitemid 26191033)
24. Ernsberger P, Friedman JE, Koletsky RJ. The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease. J Hypertens 1997; 15 (Suppl 1): S9-23. (Pubitemid 27089314)
25. Rosen P, Ohly P, Gleichmann H. Experimental benefit of moxonidine on glucose metabolism and insulin secretion in the fructose-fed rat. J Hypertens 1997; 15: S31-8.
26. Henriksen EJ, Jacob S, Fogt DL, Youngblood EB, Godicke J. Antihypertensive agent moxonidine enhances muscle glucose transport in insulin resistant rats. Hypertension 1997: in press.
27. 1-imadazoline receptors: definition, characterization, distribution and transmembrane signaling. Ann NY Acad Sci 1995; 763: 22-42.
28. Robertson RP, Halter JB, Port D. A role for alpha-adrenergic receptors in abnormal insulin secretion in diabetes mellitus. J Clin Invest 1976; 57: 791-5.
29. Ernsberger P, Damon TH, Graff LM, Schafer SG, Christen MO. Moxonidine, a centrally acting antihypertensive agent, is selective ligand for I1 imadazoline sites. J Pharmacol Exp Ther; 264: 172-82.
30. Wang X, Rondu F, Lamouri A, et al. Effect of S-21663 (PMS 812), an imidazoline derivative, on glucose tolerance and insulin secretion in a rat model of type II diabetes. J Pharmacol Exp Ther 1995; 278: 82-9. (Pubitemid 27167082)
31. Nakadate T, Nakaki T, Muraki T, Kato R. Adrenergic regulation of blood glucose levels: possible involvement of postsynaptic alpha-2-type adrenergic receptors regulating insulin release. J Pharmacol Exp Ther 1980; 215: 226-30. (Pubitemid 11102279)
32. DiTullio NW, Cielinski L, Matthews WD, Storer B. Mechanisms involved in the hyperglycemic response induced by clonidine and other alpha-2 adrenoceptor agonists. J Pharmacol Exp Ther 1984; 228: 168-73. (Pubitemid 14223397)
33. Baron AD, Brechtel G, Wallace P, Edelman SV. Rates and tissue sites of non-insulin and insulin-mediated glucose uptake in humans. Am J Physiol 1988; 255: E769-74.
34. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 1991; 87: 2246-52.
35. Tanti JF, Gremeaux T, Rochet N, Van Obberghen E, Le Marchand-Brustel Y. Effect of cyclic AMP-dependent protein kinase on insulin receptor tyrosine kinase activity. Biochem J 1987; 245: 19-26.
36. Felley CP, Felley EM, van Melle GD, Frascarolo P, Jequier E, Felber JP. Impairment of glucose disposal by infusion of triglycerides in humans: role of glycemia. Am J Physiol 1989; 256: E747-52.
37. Randle PJ, Kerbey AL, Espinal J. Mechanisms decreasing glucose oxidation in diabetes and starvation: role of lipid fuels and hormones. Diabetes Metab Rev 1988; 7: 623-38. (Pubitemid 18260936)
38. Mory G, Tesson F, Combes GM, Nechad M, Parini A. Evidence for a role for midazoline I1 binding site in rat brown adipocytes. Ann NY Acad Sci 1995; 763: 398-400.